Leap Therapeutics Inc (LPTX) Given Consensus Rating of “Strong Buy” by Brokerages

Leap Therapeutics Inc (NASDAQ:LPTX) has been given a consensus broker rating score of 1.33 (Strong Buy) from the three brokers that provide coverage for the company, Zacks Investment Research reports. One research analyst has rated the stock with a buy rating and two have assigned a strong buy rating to the company. Leap Therapeutics’ rating score has improved by 11.3% from 90 days ago as a result of various analysts’ upgrades and downgrades.

Brokerages have set a 12-month consensus price target of $14.50 for the company and are predicting that the company will post ($0.48) EPS for the current quarter, according to Zacks. Zacks has also given Leap Therapeutics an industry rank of 156 out of 255 based on the ratings given to its competitors.

Several equities research analysts have recently issued reports on LPTX shares. HC Wainwright started coverage on Leap Therapeutics in a research note on Thursday, April 12th. They issued a “buy” rating and a $12.50 price objective for the company. ValuEngine raised Leap Therapeutics from a “hold” rating to a “buy” rating in a research note on Saturday, June 2nd. Finally, Zacks Investment Research lowered Leap Therapeutics from a “hold” rating to a “sell” rating in a research note on Thursday, May 17th.

Several hedge funds have recently modified their holdings of the stock. Sphera Funds Management LTD. bought a new stake in shares of Leap Therapeutics during the 1st quarter worth approximately $3,545,000. DAFNA Capital Management LLC lifted its stake in shares of Leap Therapeutics by 84.6% during the 1st quarter. DAFNA Capital Management LLC now owns 200,000 shares of the company’s stock worth $1,660,000 after acquiring an additional 91,670 shares during the last quarter. Sabby Management LLC bought a new stake in shares of Leap Therapeutics during the 4th quarter worth approximately $558,000. JPMorgan Chase & Co. lifted its stake in shares of Leap Therapeutics by 39,223.3% during the 1st quarter. JPMorgan Chase & Co. now owns 40,503 shares of the company’s stock worth $336,000 after acquiring an additional 40,400 shares during the last quarter. Finally, Point72 Asset Management L.P. bought a new stake in shares of Leap Therapeutics during the 1st quarter worth approximately $227,000. 17.03% of the stock is owned by hedge funds and other institutional investors.

Shares of NASDAQ:LPTX traded down $0.52 during trading on Friday, hitting $8.61. The company had a trading volume of 1,442 shares, compared to its average volume of 57,820. The firm has a market capitalization of $136.89 million, a price-to-earnings ratio of -2.62 and a beta of 0.35. Leap Therapeutics has a one year low of $4.90 and a one year high of $10.25.

Leap Therapeutics (NASDAQ:LPTX) last posted its quarterly earnings data on Friday, May 11th. The company reported ($0.85) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.61) by ($0.24). analysts expect that Leap Therapeutics will post -2.23 earnings per share for the current year.

Leap Therapeutics Company Profile

Leap Therapeutics, Inc, a biopharmaceutical company, acquires and develops therapies for the treatment of cancer. The company's clinical stage programs include DKN-01, a monoclonal antibody that inhibits Dickkopf-related protein 1, which is in Phase I/II clinical trial in patients with esophagogastric, biliary tract, gynecologic, and non-small cell lung cancers, as well as hepatocellular carcinoma, a type of liver cancer.

Get a free copy of the Zacks research report on Leap Therapeutics (LPTX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Leap Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Leap Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.


Leave a Reply